Biopharmaceutical company Lipid Therapeutics has just announced the successful enrollment of the first batch of participants in a Phase III clinical trial for LT-02, the company's first-in-class highly purified phosphatidylcholine pipeline product indicated for the treatment of ulcerative colitis that works to improve colon barrier function with delayed release technology. Dr. Falk Pharma GmbH is the company's co-development partner in Europe, and will be overseeing the clinical research for this initial group of patients.
Lipid Therapeutics also revealed the US Food and Drug Administration has endorsed its Phase III procedure, allowing the company to proceed with a 500-patient study in the US. This trial's main goal is to induce remission and measure its significance with a reduction of the Mayo Disease Activity Score in participants. Together with the European Phase III trial led by Dr. Falk Pharma, Lipid Therapeutics is well on its way to gathering substantial clinical evidence for the soonest approval of LT-02 in both territories.
"The start of this pivotal Phase III with LT-02 in